Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Income towards Parent Company: 2012-2024

Historic Income towards Parent Company for Coherus Oncology (CHRS) over the last 13 years, with Dec 2024 value amounting to $28.5 million.

  • Coherus Oncology's Income towards Parent Company fell 75.61% to $9.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $540.3 million, marking a year-over-year increase of 217.73%. This contributed to the annual value of $28.5 million for FY2024, which is 111.98% up from last year.
  • As of FY2024, Coherus Oncology's Income towards Parent Company stood at $28.5 million, which was up 111.98% from -$237.9 million recorded in FY2023.
  • Coherus Oncology's Income towards Parent Company's 5-year high stood at $132.2 million during FY2020, with a 5-year trough of -$291.8 million in FY2022.
  • Its 3-year average for Income towards Parent Company is -$167.0 million, with a median of -$237.9 million in 2023.
  • Per our database at Business Quant, Coherus Oncology's Income towards Parent Company plummeted by 317.16% in 2021 and then soared by 111.98% in 2024.
  • Coherus Oncology's Income towards Parent Company (Yearly) stood at $132.2 million in 2020, then crashed by 317.16% to -$287.1 million in 2021, then decreased by 1.62% to -$291.8 million in 2022, then climbed by 18.46% to -$237.9 million in 2023, then skyrocketed by 111.98% to $28.5 million in 2024.